18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 184-191

  Kasenda, Benjamin ^a,b   Haug, Vanessa ^a   Schorb, Elisabeth ^a   Fritsch, Kristina ^a   Jurgen Finke ^a   Mix, Michael ^a   Hader, Claudia ^a   Weber, Wolfgang A ^a   Illerhaus, Gerald ^a   Meyer, Philipp T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

FDG; PCNSL; PET; Primary CNS lymphoma; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RITUXIMAB; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; IMAGE ANALYSIS; LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; GENETIC MARKER; GENETICS; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK; SCINTISCANNING; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENETIC MARKERS; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84873556156     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.108654     Document Type: Article

References (37)

1. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol. 2009;8:581-592.
2. Carrabba MG, Reni M, Foppoli M, et al. Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother. 2010;11:1263-1276.
3. Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer. 2005;104:2466-2472.
4. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512-1520.
5. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272.
6. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
7. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063-1069.
8. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353-358.
9. Hottinger AF, Iwamoto FM, Karimi S, et al. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol. 2011;70:163-169.
10. Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102:673-677.
11. Kim JA, Kim SJ, Do IG, et al. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis? Leuk Lymphoma. 2011;52:205-213.
12. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist. 2010;15:750-759.
13. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
14. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med. 2008;49:13-21.
15. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
16. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991;32:686-691.
17. 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643-4651.
18. Kawai N, Okubo S, Miyake K, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med. 2010;24:335-343.
19. Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro-Oncol. 2008;10:223-228.
20. Roelcke U, Leenders KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol. 1999;43:231-236.
21. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging. 2006;33:164-168.
22. 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neurooncol. 2010;100:225-232.
23. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
24. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-346.
25. Ney DE, Reiner AS, Panageas KS, Brown HS, DeAngelis LM, Abrey LE. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 2010;116:4605-4612.
26. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med. 2005;44:561-571.
27. Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080-2085.
28. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865-3870.
29. Illerhaus G, Marks R, Muller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319-325.
30. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147-148.
31. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
32. 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165-174.
33. Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Schafer WM. Improved visual [123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. Q J Nucl Med Mol Imaging. 2011;55:301-309.
34. Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80:159-165.
35. Deckert M, Engert A, Bruck W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25:1797-1807.
36. Schorb E, Kasenda B, Atta J, et al. Elimination of established risk-factors in primary central nervous system lymphoma: impact of high-dose chemotherapy followed by autologous stem-cell transplantation-a multicenter retrospective analysis [abstract]. Blood. 2011;118(suppl):3089.
37. Watanabe R, Tomita N, Takeuchi K, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51:279-283.